MX2022004759A - Métodos y composiciones para tratar enfermedades y trastornos hepáticos. - Google Patents
Métodos y composiciones para tratar enfermedades y trastornos hepáticos.Info
- Publication number
- MX2022004759A MX2022004759A MX2022004759A MX2022004759A MX2022004759A MX 2022004759 A MX2022004759 A MX 2022004759A MX 2022004759 A MX2022004759 A MX 2022004759A MX 2022004759 A MX2022004759 A MX 2022004759A MX 2022004759 A MX2022004759 A MX 2022004759A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- disorders
- liver diseases
- treating liver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporcionan métodos y composiciones relacionadas a composiciones que comprenden nanoportadores sintéticos que comprenden un inmunosupresor; también se proporcionan métodos y composiciones para el tratamiento preventivo y terapéutico de la toxicidad hepática, enfermedades y trastornos, tal como hepatotoxicidad inducida por inflamación, inducida por infección o inducida por fármacos.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962924143P | 2019-10-21 | 2019-10-21 | |
US201962924099P | 2019-10-21 | 2019-10-21 | |
US201962924149P | 2019-10-21 | 2019-10-21 | |
US201962924152P | 2019-10-21 | 2019-10-21 | |
US202062981564P | 2020-02-26 | 2020-02-26 | |
US202062981582P | 2020-02-26 | 2020-02-26 | |
US202062981570P | 2020-02-26 | 2020-02-26 | |
PCT/US2020/056612 WO2021081062A1 (en) | 2019-10-21 | 2020-10-21 | Methods and compositions for treating liver diseases and disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022004759A true MX2022004759A (es) | 2022-08-19 |
Family
ID=73452282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022004759A MX2022004759A (es) | 2019-10-21 | 2020-10-21 | Métodos y composiciones para tratar enfermedades y trastornos hepáticos. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210154324A1 (es) |
EP (1) | EP4048269A1 (es) |
JP (1) | JP2022553345A (es) |
CN (1) | CN115038441A (es) |
AU (1) | AU2020370129A1 (es) |
CA (1) | CA3158408A1 (es) |
IL (1) | IL292392A (es) |
MX (1) | MX2022004759A (es) |
WO (1) | WO2021081062A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA027410B1 (ru) | 2011-04-29 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Наноносители, вызывающие иммунную толерантность, для снижения ответной реакции цитотоксических t-лимфоцитов |
CN105338968A (zh) | 2013-05-03 | 2016-02-17 | 西莱克塔生物科技公司 | 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体 |
CA2957737A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
BR112019018748A2 (pt) | 2017-03-11 | 2020-04-07 | Selecta Biosciences Inc | métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1995A (en) | 1841-03-03 | Latch of door and other locks | ||
US934897A (en) | 1907-08-08 | 1909-09-21 | Frank Dutcher | Fusee-cap. |
US927297A (en) | 1908-02-24 | 1909-07-06 | Charles Tuckfield | Engine. |
US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
AU4724401A (en) | 2000-02-28 | 2001-09-12 | Genesegues Inc | Nanocapsule encapsulation system and method |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
WO2003020797A1 (en) | 2001-08-30 | 2003-03-13 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
AU2004318602B2 (en) | 2003-12-19 | 2009-12-10 | The University Of North Carolina At Chapel Hill | Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography |
JP2008512350A (ja) | 2004-07-01 | 2008-04-24 | イェール ユニバーシティ | 標的化され、そして高密度で薬物が負荷されるポリマー性物質 |
CA2684052A1 (en) | 2007-04-12 | 2008-10-23 | Emory University | Novel strategies for delivery of active agents using micelles and particles |
JP2011500569A (ja) | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
EA027410B1 (ru) * | 2011-04-29 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Наноносители, вызывающие иммунную толерантность, для снижения ответной реакции цитотоксических t-лимфоцитов |
ES2846809T3 (es) | 2014-11-05 | 2021-07-29 | Selecta Biosciences Inc | Métodos y composiciones relacionadas con el uso de tensioactivos de bajo HLB en la producción de nanovehículos sintéticos que comprenden un rapalogo |
MX2018011012A (es) * | 2016-03-11 | 2019-03-28 | Selecta Biosciences Inc | Formulaciones y dosis de uricasa pegilada. |
BR112019018748A2 (pt) * | 2017-03-11 | 2020-04-07 | Selecta Biosciences Inc | métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor |
CA3138525A1 (en) * | 2019-04-28 | 2020-11-05 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
-
2020
- 2020-10-21 JP JP2022523625A patent/JP2022553345A/ja active Pending
- 2020-10-21 WO PCT/US2020/056612 patent/WO2021081062A1/en unknown
- 2020-10-21 MX MX2022004759A patent/MX2022004759A/es unknown
- 2020-10-21 IL IL292392A patent/IL292392A/en unknown
- 2020-10-21 CA CA3158408A patent/CA3158408A1/en active Pending
- 2020-10-21 CN CN202080088657.1A patent/CN115038441A/zh active Pending
- 2020-10-21 US US17/076,080 patent/US20210154324A1/en active Pending
- 2020-10-21 EP EP20807945.9A patent/EP4048269A1/en active Pending
- 2020-10-21 AU AU2020370129A patent/AU2020370129A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115038441A (zh) | 2022-09-09 |
US20210154324A1 (en) | 2021-05-27 |
JP2022553345A (ja) | 2022-12-22 |
WO2021081062A1 (en) | 2021-04-29 |
CA3158408A1 (en) | 2021-04-29 |
AU2020370129A1 (en) | 2022-05-12 |
EP4048269A1 (en) | 2022-08-31 |
IL292392A (en) | 2022-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022004759A (es) | Métodos y composiciones para tratar enfermedades y trastornos hepáticos. | |
EP4234551A3 (en) | Pyridazinones as parp7 inhibitors | |
MX2022001295A (es) | Inhibidores de kif18a. | |
PH12017502203A1 (en) | Tyrosine kinase inhibitors | |
WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
WO2022031847A3 (en) | Compositions and methods for inhibiting plp1 expression | |
CR20220207A (es) | Compuestos terapéuticos y métodos de uso | |
CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
MX2021004598A (es) | Inhibidores selectivos de rgmc y el uso de los mismos. | |
MX2022003671A (es) | Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades. | |
MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
MX2021008712A (es) | Derivados heterociclicos. | |
MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
MX2018005515A (es) | Derivados de 1,4-dicarbonil-piperidilo. | |
ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
MX2019007041A (es) | Metodos y composiciones para tratar la enfermedad de parkinson. | |
MX2022002446A (es) | Compuestos de pirrolopirimidina inhibidores de perk. | |
WO2018211324A8 (en) | Prodrugs for the treatment of disease |